menu
    • menu
    [{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"Gylden Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"DengueTcP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DEKA Research & Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"DEKA Research & Development \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"6","companyTruncated":"DEKA Research & Development \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"DEKA Research & Development","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"DEKA Research & Development \/ DEKA Research & Development","highestDevelopmentStatusID":"15","companyTruncated":"DEKA Research & Development \/ DEKA Research & Development"},{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"Zealand Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"DEKA Research & Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"DEKA Research & Development \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"DEKA Research & Development \/ Zealand Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by DEKA Research & Development

    Menu

    DEKA Research & Development

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DEKA Research & Development

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            DEKA Research & Development

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DengueTcP

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Gylden Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Emergex Partners with DEKA for Assessment of Immunotherapeutic Candidates with Applicator

                            Details : The collaboration aims to assess the compatibility of Emergex’s immunotherapeutic candidates, including EMX-001 (dengueTcP) with the DEKA Intradermal Therapeutic Applicator.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 16, 2024

                            Lead Product(s) : DengueTcP

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Gylden Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DEKA Research & Development

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            DEKA Research & Development

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasiglucagon

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Zealand Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development o...

                            Details : Under the terms of the agreement, DEKA and Zealand will develop a medical pump system that is suitable for use in combination with dasiglucagon. DEKA and its affiliates will be responsible for pump development and pump manufacturing activities.

                            Product Name : Zegalogue

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            May 11, 2021

                            Lead Product(s) : Dasiglucagon

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Zealand Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DEKA Research & Development

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            DEKA Research & Development

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : United Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery Syst...

                            Details : Remodulin (treprostinil) is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise.

                            Product Name : Remodulin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 24, 2021

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : United Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth